# Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

Study · id `cardio:ct-nct05425719` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05425719](<https://clinicaltrials.gov/study/NCT05425719>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05425719

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 249 participants.

## Technical summary

Registry record NCT05425719. Non-randomized; no masking; primary purpose other. Start 2022-06-14 (actual); primary completion 2023-02-15 (actual). Results posted on 2024-04-18.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose other
- Phase: Phase 3
- Enrolled: 249 participants (enrolled count; ClinicalTrials.gov record NCT05425719, source copy `cardio:ctgov-nct05425719-2024-04-18`, retrieved 2026-10-31)
- Started: 2022-06-14 (actual) (ClinicalTrials.gov record NCT05425719, source copy `cardio:ctgov-nct05425719-2024-04-18`, retrieved 2026-10-31)
- Primary completion: 2023-02-15 (actual) (ClinicalTrials.gov record NCT05425719, source copy `cardio:ctgov-nct05425719-2024-04-18`, retrieved 2026-10-31)
- Completion: 2023-02-15 (actual) (ClinicalTrials.gov record NCT05425719, source copy `cardio:ctgov-nct05425719-2024-04-18`, retrieved 2026-10-31)
- Results first posted: 2024-04-18 (ClinicalTrials.gov record NCT05425719, source copy `cardio:ctgov-nct05425719-2024-04-18`, retrieved 2026-10-31)
- Countries: United States; China (ClinicalTrials.gov record NCT05425719, source copy `cardio:ctgov-nct05425719-2024-04-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05425719-2024-04-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
- Condition: Chronic Kidney Disease
- Intervention (Drug): MB-102
- Intervention (Device): MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Lead sponsor: MediBeacon
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: c26af8ec7fb2469c8281b5e9b6e3a7d097db33001462a350ce0bc1a9c30eea03
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
